Q2 EPS Estimate for Avalo Therapeutics Lifted by Analyst

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Equities research analysts at Wedbush lifted their Q2 2025 earnings estimates for shares of Avalo Therapeutics in a report released on Thursday, March 20th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($1.25) for the quarter, up from their prior estimate of ($1.40). Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics’ Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($0.94) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($1.40) EPS.

Several other brokerages also recently issued reports on AVTX. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday. Finally, BTIG Research assumed coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Avalo Therapeutics Trading Down 6.8 %

AVTX stock opened at $7.66 on Monday. The company has a 50 day simple moving average of $7.45 and a 200 day simple moving average of $9.13. Avalo Therapeutics has a 1 year low of $4.60 and a 1 year high of $34.46.

Institutional Trading of Avalo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its holdings in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP bought a new position in shares of Avalo Therapeutics during the fourth quarter worth about $114,000. Walleye Capital LLC acquired a new position in shares of Avalo Therapeutics in the fourth quarter worth approximately $145,000. Northern Trust Corp bought a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $168,000. Finally, Bank of Montreal Can acquired a new stake in Avalo Therapeutics during the 4th quarter valued at approximately $446,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.